These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11308267)

  • 1. Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
    Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):1-2. PubMed ID: 11308267
    [No Abstract]   [Full Text] [Related]  

  • 2. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
    Heatherington AC; Schuller J; Mercer AJ
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):11-6. PubMed ID: 11308269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
    Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
    Macdougall IC
    Curr Hematol Rep; 2005 Nov; 4(6):436-40. PubMed ID: 16232379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
    Glaspy J; Jadeja JS; Justice G; Kessler J; Richards D; Schwartzberg L; Rigas J; Kuter D; Harmon D; Prow D; Demetri G; Gordon D; Arseneau J; Saven A; Hynes H; Boccia R; O'Byrne J; Colowick AB
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):17-23. PubMed ID: 11308270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
    Nissenson AR
    Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
    Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
    Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa in anemia management: a vital role in cancer care.
    Boccia R
    J Support Oncol; 2005; 3(2 Suppl 1):3-5. PubMed ID: 15794499
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 17. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 20. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.